Effect of a combined administration of 5-fluorouracil and medroxyprogesterone acetate on pyrimidine nucleoside phosphorylases and thymidylate synthetase in 7,12-dimethylbenz

Oncol Rep. 2001 May-Jun;8(3):543-6. doi: 10.3892/or.8.3.543.

Abstract

The effect of a combined therapy of medroxyprogesterone acetate (MPA) and 5-fluorouracil (5-FU) on tumor size, pyrimidine nucleoside phosphorylase (PyNPase) activity, and thymidylate synthetase (TS) activity was examined in Sprague-Dawley (SD) rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. MPA augmented the antitumor activity of 5-FU and protected against body weight-loss due to 5-FU administration. PyNPase activity of both the MPA group and the MPA+5-FU group tended to increase compared with that of the 5-FU alone group. TS inhibition levels in the MPA+5-FU group tended to increase compared with those in the 5-FU alone group. These results indicate that MPA tended to augment antitumor activity of 5-FU and to reduce the side effects caused by 5-FU.

MeSH terms

  • 9,10-Dimethyl-1,2-benzanthracene
  • Animals
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Body Weight
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / therapeutic use*
  • Mammary Neoplasms, Experimental / chemically induced
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / enzymology
  • Medroxyprogesterone Acetate / therapeutic use*
  • Pentosyltransferases / metabolism*
  • Pyrimidine Phosphorylases
  • Rats
  • Rats, Sprague-Dawley
  • Thymidylate Synthase / metabolism*

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Hormonal
  • 9,10-Dimethyl-1,2-benzanthracene
  • Medroxyprogesterone Acetate
  • Thymidylate Synthase
  • Pentosyltransferases
  • Pyrimidine Phosphorylases
  • Fluorouracil